Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D M Barnes

Showing results (231-240 of 285) with videos related to

Pageof 29
Sort By:
Journal of Medical Genetics|March 1, 1995
Heterogeneity in Li-Fraumeni families: p53 mutation analysis and immunohistochemical stainingC MacGeoch, G Turner, L G Bobrow, et al.
British Journal of Cancer|August 1, 1986
Expression of epidermal growth factor receptor (EGF-R) in human lung tumoursT Cerny, D M Barnes, P Hasleton, et al.
The Journal of Pathology|March 13, 1998
The localization of the insulin-like growth factor receptor 1 (IGFR-1) in benign and malignant breast tissueL C Happerfield, D W Miles, D M Barnes, et al.
International Journal of Cancer|March 12, 1998
Retinoblastoma and p16 proteins in mammary carcinoma: their relationship to cyclin D1 and histopathological parametersE A Dublin, N K Patel, C E Gillett, et al.
Cancer Research|January 1, 1987
Endocrine therapy for advanced carcinoma of the breast: effect of tumor heterogeneity and site of biopsy on the predictive value of progesterone receptor estimationsA Howell, R N Harland, D M Barnes, et al.
Oncogene|April 17, 1997
Two functional assays employed to detect an unusual mutation in the oligomerisation domain of p53 in a Li-Fraumeni like familyM E Lomax, D M Barnes, R Gilchrist, et al.
British Journal of Cancer|April 1, 1993
Ki-S1, a novel proliferative marker: flow cytometric assessment of staining in human breast carcinoma cellsR S Camplejohn, A Brock, D M Barnes, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1992
Overexpression of the c-erbB-2 oncoprotein: why does this occur more frequently in ductal carcinoma in situ than in invasive mammary carcinoma and is this of prognostic significance?D M Barnes, J Bartkova, R S Camplejohn, et al.
British Journal of Cancer|March 1, 1991
The relationship between c-erbB-2 expression, S-phase fraction and prognosis in breast cancerS M O'Reilly, D M Barnes, R S Camplejohn, et al.
British Journal of Cancer|March 31, 1999
Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancerS J Houston, T A Plunkett, D M Barnes, et al.
Pageof 29

Showing results (231-240 of 285) with videos related to

Sort By:
Pageof 29
Journal of Medical Genetics|March 1, 1995
Heterogeneity in Li-Fraumeni families: p53 mutation analysis and immunohistochemical stainingC MacGeoch, G Turner, L G Bobrow, et al.
British Journal of Cancer|August 1, 1986
Expression of epidermal growth factor receptor (EGF-R) in human lung tumoursT Cerny, D M Barnes, P Hasleton, et al.
The Journal of Pathology|March 13, 1998
The localization of the insulin-like growth factor receptor 1 (IGFR-1) in benign and malignant breast tissueL C Happerfield, D W Miles, D M Barnes, et al.
International Journal of Cancer|March 12, 1998
Retinoblastoma and p16 proteins in mammary carcinoma: their relationship to cyclin D1 and histopathological parametersE A Dublin, N K Patel, C E Gillett, et al.
Cancer Research|January 1, 1987
Endocrine therapy for advanced carcinoma of the breast: effect of tumor heterogeneity and site of biopsy on the predictive value of progesterone receptor estimationsA Howell, R N Harland, D M Barnes, et al.
Oncogene|April 17, 1997
Two functional assays employed to detect an unusual mutation in the oligomerisation domain of p53 in a Li-Fraumeni like familyM E Lomax, D M Barnes, R Gilchrist, et al.
British Journal of Cancer|April 1, 1993
Ki-S1, a novel proliferative marker: flow cytometric assessment of staining in human breast carcinoma cellsR S Camplejohn, A Brock, D M Barnes, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1992
Overexpression of the c-erbB-2 oncoprotein: why does this occur more frequently in ductal carcinoma in situ than in invasive mammary carcinoma and is this of prognostic significance?D M Barnes, J Bartkova, R S Camplejohn, et al.
British Journal of Cancer|March 1, 1991
The relationship between c-erbB-2 expression, S-phase fraction and prognosis in breast cancerS M O'Reilly, D M Barnes, R S Camplejohn, et al.
British Journal of Cancer|March 31, 1999
Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancerS J Houston, T A Plunkett, D M Barnes, et al.
Pageof 29